Understanding The Complexity Of Antigen Presentation
Funder
National Health and Medical Research Council
Funding Amount
$774,540.00
Summary
I have developed and established the use of mass spectrometry to identify and quantitate ligands of antigen presenting molecules to understand the breadth of immune responses in a variety of human disease states including autoimmunity, cancer, infection and allergy. By embedding the technology in disease focussed research programs I will define the molecular bases of these diseases and the important immunological targets that will provide new avenues for therapeutic development and vaccines.
A Proteome-wide Approach To Anti-viral Immunity And Vaccine Development
Funder
National Health and Medical Research Council
Funding Amount
$622,655.00
Summary
We know that many parts of viruses are displayed to the immune system, but at present the exact fragments are difficult to predict, we do not know all the genes in our bodies that control this process and we also need better methods to study the way some viruses (e.g. the cold sore virus) avoid detection. This project will study these problems with the overall goal of improving vaccine design, understanding immune deficiency and how viruses fight back against our immune system.
Biochemistry And Cell Biology Of Antigen Presentation And T Cell Activation
Funder
National Health and Medical Research Council
Funding Amount
$763,409.00
Summary
José Villadangos studies the cells and molecules involved in Antigen Presentation. This phenomenon consists of the detection, capture and display of microbe fragments on the surface of Antigen Presenting Cells (APC) for recognition by T cells. This initiates an immune response that culminates in the deployment of cells and molecules armed to fight the infection. His research may lead to development of more effective vaccines and prevention of autoimmunity, allergy and transplant rejection.
T cells play a pivotal role in the immune system by recognising viral peptides presented by "HLA" molecules on infected cells through the use of T cell receptors (TCRs). I will investigate the variables that influence T lymphocyte recognition of human herpesvirus infection, including variability in TCR, HLA, and viral genes. Understanding the impact of these variables on how we fight infections will aid in the development of new "intelligent" vaccines and immune-based therapies.
Understanding Determinant Selection In Autoimmune Diseases
Funder
National Health and Medical Research Council
Funding Amount
$686,656.00
Summary
Understanding what the immune system perceives during infection or in autoimmunity is key to the development of improved vaccines and therapies for a variety of human diseases. This proposal builds on leading research into the definition of targets of immunity in autoimmune diseases using cutting edge proteomic technologies. The proposal focuses on type 1 diabetes, multiple sclerosis, lupus and rheumatoid arthritis and will delineate candidate therapeutic molecules.
Antigen-presenting cells control immune responses. Different types of these cells do different jobs and affect different diseases. We wish to control these processes by determining how the cells live and die. In particular we are interested in controlling the local immune responses during rejection of islet transplantation, which can cure type 1 diabetes.
Structure-based And Fragment-based Approaches To Developing New Therapeutics
Funder
National Health and Medical Research Council
Funding Amount
$763,409.00
Summary
Two powerful and complementary approaches to developing new drugs will be combined to target proteins that play key roles in malaria and other parasite and bacterial infections with the aim of developing new therapeutics. In addition, the potential of peptide toxins to treat autoimmune diseases such as multiple sclerosis, as well as chronic pain and other conditions, will be exploited to develop new drugs.
Immune Imprinting By Nanoparticles And Vaccines: New Principles And Translation Into The Clinic
Funder
National Health and Medical Research Council
Funding Amount
$631,010.00
Summary
Vaccines require adjuvants to be effective. Despite decades of research there is only one adjuvant approved for broad use in humans. Based on our prior findings I will engage new principles in nanotechnology, and deepen understanding of immune imprinting in various organs of the body including the lung, to develop 2nd generation broadly useful nanoadjuvants able to effectively treat cancer and malaria.
Discovering How MicroRNAs And CircRNAs Control Cancer Metastasis
Funder
National Health and Medical Research Council
Funding Amount
$763,845.00
Summary
Most cancers arise from epithelial cells, and most deaths from these cancers are due to the transition of the cancer to an invasive form, that can invade tissues and establish secondary cancers (metastases). Our work will focus on understanding how recently discovered gene regulators, called microRNAs and circular RNAs, control changes in cancer cells to allow them to progress to invasive, metastatic forms and use this knowledge to find ways to block the process.
MicroRNA Pathway Control Of Immune Cell Development
Funder
National Health and Medical Research Council
Funding Amount
$631,370.00
Summary
The immune system is comprised of many different cell types, each with a specialised function. Many are short-lived and must be continually replenished throughout life. Abnormalities in this process underlie many human diseases, including immunodeficiency, autoimmunity and cancer. My laboratory seeks to understand the molecular pathways that control development of immune cells and to identify the defects that lead to disease.